ATE229977T1 - Peptide mit antiproliferativen eigenschaften - Google Patents
Peptide mit antiproliferativen eigenschaftenInfo
- Publication number
- ATE229977T1 ATE229977T1 AT97918058T AT97918058T ATE229977T1 AT E229977 T1 ATE229977 T1 AT E229977T1 AT 97918058 T AT97918058 T AT 97918058T AT 97918058 T AT97918058 T AT 97918058T AT E229977 T1 ATE229977 T1 AT E229977T1
- Authority
- AT
- Austria
- Prior art keywords
- peptides
- nucleic acids
- growth factor
- relates
- segments
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 230000001028 anti-proliverative effect Effects 0.000 title abstract 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091093037 Peptide nucleic acid Proteins 0.000 abstract 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 abstract 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000000225 tumor suppressor protein Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19611939 | 1996-03-26 | ||
| DE19653445A DE19653445C1 (de) | 1996-03-26 | 1996-12-20 | Peptide mit antineoplastischen Eigenschaften |
| PCT/DE1997/000643 WO1997035873A2 (de) | 1996-03-26 | 1997-03-26 | Peptide mit antiproliferativen eigenschaften |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE229977T1 true ATE229977T1 (de) | 2003-01-15 |
Family
ID=26024147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97918058T ATE229977T1 (de) | 1996-03-26 | 1997-03-26 | Peptide mit antiproliferativen eigenschaften |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6660830B1 (https=) |
| EP (1) | EP0892811B1 (https=) |
| JP (1) | JP2001508643A (https=) |
| CN (1) | CN1214694A (https=) |
| AT (1) | ATE229977T1 (https=) |
| AU (1) | AU727662B2 (https=) |
| BR (1) | BR9711795A (https=) |
| CA (1) | CA2251691A1 (https=) |
| NO (1) | NO984415L (https=) |
| WO (1) | WO1997035873A2 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2400567T3 (es) | 2004-04-21 | 2013-04-10 | The University Of Chicago | Inhibidores de cinasa de la cadena ligera de miosina y su uso |
| US7947645B2 (en) * | 2004-09-02 | 2011-05-24 | Cognosci, Inc. | APO E analogs and methods for their use |
| KR101364374B1 (ko) * | 2005-03-14 | 2014-02-17 | 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | 생활성 ｆｕｓ1 펩티드 및 나노입자-폴리펩티드 복합체 |
| KR100729830B1 (ko) * | 2005-03-24 | 2007-06-19 | 바이오스펙트럼 주식회사 | 페너트라틴을 이용하여 단백질의 세포투과를 증진시키는대장균용발현벡터 |
| US9243035B2 (en) * | 2013-11-26 | 2016-01-26 | Nymox Corporation | Peptides effective in the treatment of conditions requiring the removal or destruction of cells |
| US10513711B2 (en) | 2014-08-13 | 2019-12-24 | Dupont Us Holding, Llc | Genetic targeting in non-conventional yeast using an RNA-guided endonuclease |
| CN107406838A (zh) | 2014-11-06 | 2017-11-28 | 纳幕尔杜邦公司 | Rna引导的内切核酸酶向细胞中的肽介导的递送 |
| US11628202B2 (en) | 2015-07-24 | 2023-04-18 | Nymox Corporation | Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia |
| AU2016338785B2 (en) | 2015-10-12 | 2022-07-14 | E. I. Du Pont De Nemours And Company | Protected DNA templates for gene modification and increased homologous recombination in cells and methods of use |
| EP3365440B1 (en) | 2015-10-20 | 2022-09-14 | Pioneer Hi-Bred International, Inc. | Restoring function to a non-functional gene product via guided cas systems and methods of use |
| WO2017079026A1 (en) | 2015-11-06 | 2017-05-11 | E. I. Du Pont De Nemours And Company | Generation of complex trait loci in soybean and methods of use |
| EP3699281A1 (en) | 2016-03-11 | 2020-08-26 | Pioneer Hi-Bred International, Inc. | Novel cas9 systems and methods of use |
| AU2017286122A1 (en) | 2016-06-14 | 2018-11-22 | Pioneer Hi-Bred International, Inc. | Use of Cpf1 endonuclease for plant genome modifications |
| US10183058B2 (en) | 2016-06-17 | 2019-01-22 | Nymox Corporation | Method of preventing or reducing the progression of prostate cancer |
| CA3018430A1 (en) | 2016-06-20 | 2017-12-28 | Pioneer Hi-Bred International, Inc. | Novel cas systems and methods of use |
| US10172910B2 (en) | 2016-07-28 | 2019-01-08 | Nymox Corporation | Method of preventing or reducing the incidence of acute urinary retention |
| US10532081B2 (en) | 2016-09-07 | 2020-01-14 | Nymox Corporation | Method of ameliorating or preventing the worsening or the progression of symptoms of BPH |
| US11519009B2 (en) | 2017-01-09 | 2022-12-06 | University Of Massachusetts | Complexes for gene deletion and editing |
| US10335453B2 (en) | 2017-03-01 | 2019-07-02 | Nymox Corporation | Compositions and methods for improving sexual function |
| CN111465689B (zh) | 2017-12-15 | 2024-07-12 | 丹尼斯科美国公司 | Cas9变体和使用方法 |
| KR20200124702A (ko) | 2018-02-23 | 2020-11-03 | 파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 | 신규한 cas9 오르소로그 |
| US12365888B2 (en) | 2018-12-14 | 2025-07-22 | Pioneer Hi-Bred International, Inc. | CRISPR-Cas systems for genome editing |
| CA3136113A1 (en) | 2019-04-05 | 2020-10-08 | Danisco Us Inc. | Methods for polynucleotide integration into the genome of bacillus using dual circular recombinant dna constructs and compositions thereof |
| US20220177923A1 (en) | 2019-04-05 | 2022-06-09 | Danisco Us Inc | Methods for integrating a donor DNA sequence into the genome of bacillus using linear recombinant DNA constructs and compositions thereof |
| EP4627078A1 (en) | 2022-12-01 | 2025-10-08 | Danisco US Inc. | Iterative muliplex genome engineering in microbial cells using a bidirectional selection marker system |
| WO2024118882A1 (en) | 2022-12-01 | 2024-06-06 | Genencor International Bv | Iterative multiplex genome engineering in microbial cells using a selection marker swapping system |
| WO2024118876A1 (en) | 2022-12-01 | 2024-06-06 | Genencor International Bv | Iterative multiplex genome engineering in microbial cells using a recombinant self-excisable selection marker system |
| CN121152874A (zh) | 2023-03-20 | 2025-12-16 | 先锋国际良种公司 | 具有改变的PAM识别的Cas多肽 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851991A (en) * | 1987-08-31 | 1998-12-22 | The Regents Of The University Of California | Therapeutic use of the retinoblastoma susceptibility gene product |
| WO1989006703A1 (en) * | 1988-01-21 | 1989-07-27 | Massachusetts Eye And Ear Infirmary | Diagnosis of retinoblastoma |
| US5539082A (en) * | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| IL106760A (en) * | 1992-08-25 | 1999-12-31 | Miles Inc | Protein-nucleic acid hybrid construct for translocating an exogenous nucleic acid into a target cell and nucleus |
| DE4237129A1 (de) * | 1992-11-03 | 1994-05-05 | Radulescu Razvan Tudor Dr Med | Anwendung der Komplementärpeptid-Theorie in der Onkologie/Kartiologie: 1. VPH = NH¶2¶-len alphaN-Me-Phe Tyr Lys alphaN-Me-Lys Val D-Tyr-COOH 2. Kalziumantagonist auf der Basis eines Komplementärpeptides zur Calmodulinbindungsstelle 3.hSNI¶B¶¶1¶¶6¶¶-¶¶2¶¶1¶[3'->5'] = NH¶2¶-Len Pro Thr His Asp Ala-COOH |
| US5625031A (en) * | 1994-02-08 | 1997-04-29 | Bristol-Myers Squibb Company | Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein |
| EP0685493A1 (en) * | 1994-06-01 | 1995-12-06 | CANJI, Inc. | Tumor suppressor fusion proteins |
| WO1995034647A1 (en) * | 1994-06-13 | 1995-12-21 | Vanderbilt University | Compositions for and methods of enhancing delivery of nucleic acids to cells |
| US5573925A (en) * | 1994-11-28 | 1996-11-12 | The Wistar Institute Of Anatomy And Biology | P53 proteins with altered tetramerization domains |
| DE19526174C2 (de) * | 1995-07-18 | 1998-02-26 | Friedhelm Prof Dr Herrmann | Mittel gegen Tumorwachstum |
-
1997
- 1997-03-26 US US09/155,165 patent/US6660830B1/en not_active Expired - Fee Related
- 1997-03-26 WO PCT/DE1997/000643 patent/WO1997035873A2/de not_active Ceased
- 1997-03-26 CA CA002251691A patent/CA2251691A1/en not_active Abandoned
- 1997-03-26 BR BR9711795-1A patent/BR9711795A/pt not_active Application Discontinuation
- 1997-03-26 AU AU26334/97A patent/AU727662B2/en not_active Ceased
- 1997-03-26 AT AT97918058T patent/ATE229977T1/de not_active IP Right Cessation
- 1997-03-26 JP JP53394197A patent/JP2001508643A/ja not_active Ceased
- 1997-03-26 CN CN97193351A patent/CN1214694A/zh active Pending
- 1997-03-26 EP EP97918058A patent/EP0892811B1/de not_active Expired - Lifetime
-
1998
- 1998-09-22 NO NO984415A patent/NO984415L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997035873A3 (de) | 1997-12-31 |
| JP2001508643A (ja) | 2001-07-03 |
| EP0892811A2 (de) | 1999-01-27 |
| CN1214694A (zh) | 1999-04-21 |
| US6660830B1 (en) | 2003-12-09 |
| EP0892811B1 (de) | 2002-12-18 |
| WO1997035873A2 (de) | 1997-10-02 |
| AU727662B2 (en) | 2000-12-21 |
| AU2633497A (en) | 1997-10-17 |
| BR9711795A (pt) | 2000-06-06 |
| NO984415D0 (no) | 1998-09-22 |
| NO984415L (no) | 1998-09-22 |
| CA2251691A1 (en) | 1997-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE229977T1 (de) | Peptide mit antiproliferativen eigenschaften | |
| BR0009505A (pt) | Compostos e processos para terapia e diagnóstico de câncer de pulmão | |
| DK0814827T3 (da) | Karendotel-vækstfaktor-B | |
| DK1005540T3 (da) | IKK-beta-proteiner, nukleinsyrer og fremgangsmåder | |
| RU95115239A (ru) | Аналог эритропоэтина | |
| ATE382055T1 (de) | Wnt-1 verwandte polypeptide und dafür kodierende nukleinsäuren | |
| BR0316435A (pt) | Produtos genéticos expressos diferencialmente em tumores e uso dos mesmos | |
| DE69637148D1 (de) | Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen | |
| ATE315087T1 (de) | Neuartige auf p53 ansprechende gene | |
| ATE418563T1 (de) | Nik proteine, nukleinsäure sowie verfahren | |
| ATE380867T1 (de) | Lactoferrinrezeptorgen von moraxella | |
| DK1025236T3 (da) | Human checkpoint kinase, HCDS1, præparater og fremgangsmåde | |
| SE9602496D0 (sv) | Method and means for producing a fibrinogen binding protein and its use in biotechnology | |
| EP1536006A4 (en) | CANCER-ANIMALS AND THEIR USE | |
| CA2294566A1 (en) | Ikk-.alpha. proteins, nucleic acids and methods | |
| FR2744455B1 (fr) | Nouvelles sequences d'acides nucleiques de la famille des facteurs suppresseurs de tumeurs, produits d'expression correspondants et leurs applications | |
| EP0815240A4 (en) | NEW HUMAN PROTEINS, LIKE CYCLINE-DEPENDENT KINASES, AND METHODS TO USE THEM | |
| EA199800862A1 (ru) | Пептиды, обладающие антипролиферативными свойствами | |
| AU6839900A (en) | Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, and comprising at least one intron sequence | |
| DK1105485T3 (da) | Human IL-1-epsilon-DNA og polypeptider | |
| WO1998012220A3 (en) | Novel tumor proteins | |
| WO2001040271A3 (en) | Cancer associated antigens and uses therefor | |
| WO2002077190A3 (en) | Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof | |
| WO2002064628A3 (en) | Isolated human transporter proteins nucleic acids and use thereof | |
| WO2002068468A3 (en) | Isolated human tumor supressor proteins, nucleic acid molecules encoding these human tumor supressor proteins, and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REN | Ceased due to non-payment of the annual fee |